A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes

NCT01455909 on ClinicalTrials.gov · last registry update 2012-12-25

Withdrawn before anyone was enrolled. Its estimated completion date, July 2014, has passed with no update to the record. Primary outcome, as filed: Change in HbA1c. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: WITHDRAWN
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: Intarcia Therapeutics
Sponsor type: Industry
Enrollment: 0
Started: 2013-02
Primary completion: 2014-07 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.